Oruka Therapeutics (ORKA) Stock: Buy, Sell, or Hold?
ORKA - Oruka Therapeutics, Inc. Common Stock
$81.15
1.23 (1.54%)
▲
5d:
+9.86%
30d:
-9.76%
90d:
-11.95%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 11, 2026
18d
Get Alerted When ORKA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ORKA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ORKA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ORKA is currently trading at $81.15, which is considered fair relative to its 30-day fair value range of $77.09 to $91.10.
Technical Outlook: Technically, ORKA is in a uptrend. The price is approaching resistance at $82.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ORKA scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (9th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $155.00 (+91.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ORKA is in a uptrend. The price is approaching resistance at $82.95. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ORKA scores 67/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (9th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $155.00 (+91.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$77.09 -
$91.10
Company Quality Score
63/100
(BUY)
Options IV Signal
9th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 9th percentile)
- BULLISH: Strong technical setup (67/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 91.0% below Wall St target ($155.00)
- BULLISH: Bottoming setup score 67/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$77.09 -
$91.10
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$7.71
(9.5%)
Support & Resistance Levels
Support Level
$70.50
Resistance Level
$82.95
Current Trend
Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.35
Wall Street Target
$155.00
(+91.0%)
Share & Embed Analysis
Last updated: October 23, 2026 5:39 AM ET
Data refreshes hourly during market hours. Next update: 6:39 AM
Data refreshes hourly during market hours. Next update: 6:39 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORKA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 49 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 39 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 70 BUY |
